Kaufmann J O, Krapels I P C, Van Brussel B T J, Zekveld-Vroon R C, Oosterwijk J C, van Erp F, van Echtelt J, Zwijnenburg P J G, Petrij F, Bakker E, Giordano P C
The Hemoglobinopathies Laboratory, Department of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Public Health Genomics. 2014;17(1):16-22. doi: 10.1159/000355223. Epub 2013 Nov 8.
Universal newborn screening for hemoglobinopathies started in The Netherlands in 2007. Herewith severe conditions, such as sickle cell disease, β-thalassemia major and hemoglobin H disease are putatively identified. Additionally, at least 1,800 carriers of hemoglobin variants associated with severe conditions in homozygote or compound heterozygote forms are identified yearly. Thus far, approximately 60 patients and 800 healthy sickle cell (HbS) carriers are reported each year among 180,000 newborns. Results are sent to the general practitioner with the recommendation to inform and diagnose both parents of the healthy carriers to exclude genetic risk, while patients and their parents are referred directly to a pediatrician. This study was performed to determine how often parents of identified carriers and affected newborns are seen in genetic centers for counseling.
In this retrospective study, we collected anonymized data from 7 of the 8 Dutch clinical genetic centers from January 1, 2007, until December 31, 2010.
After an initial general increase in total counseling intakes, a decline was noticed in the third year, while the requests for prenatal diagnoses remained relatively stable. In 2007 and 2013, genetic counselors were asked for self-reported knowledge. They found hemoglobinopathy counseling complex, but by 2013, they indicated they had acquired sufficient knowledge on most hemoglobinopathy aspects.
We could not observe a significant increase in genetic counseling for hemoglobinopathy after its introduction into newborn screening. Although 120 HbS carriers and 60 patients are expected to be born from couples at risk annually, only 33 at risk couples out of 540 families of diagnosed newborns received optimal care and information at a genetics center in 4 years.
荷兰于2007年开始对血红蛋白病进行新生儿普遍筛查。借此可初步识别镰状细胞病、重型β地中海贫血和血红蛋白H病等严重病症。此外,每年可识别出至少1800名以纯合子或复合杂合子形式携带与严重病症相关的血红蛋白变异体的携带者。到目前为止,在180,000名新生儿中,每年报告约60例患者和800名健康的镰状细胞(HbS)携带者。结果会发送给全科医生,并建议告知并诊断健康携带者的父母以排除遗传风险,而患者及其父母则被直接转诊至儿科医生处。本研究旨在确定已识别携带者和患病新生儿的父母在遗传中心接受咨询的频率。
在这项回顾性研究中,我们收集了荷兰8个临床遗传中心中7个中心从2007年1月1日至2010年12月31日的匿名数据。
在咨询总量最初普遍增加之后,第三年出现了下降,而产前诊断的需求保持相对稳定。在2007年和2013年,遗传咨询师被要求报告自身知识水平。他们发现血红蛋白病咨询很复杂,但到2013年,他们表示已在大多数血红蛋白病方面掌握了足够的知识。
在将血红蛋白病纳入新生儿筛查后,我们未观察到遗传咨询显著增加。尽管预计每年有120名HbS携带者和60例患者出生于有风险的夫妇,但在4年时间里,540个已诊断新生儿家庭中只有33对有风险的夫妇在遗传中心获得了最佳护理和信息。